Does the initiation of SGLT2 inhibitors reduce the risk of acute kidney injury compared to other novel glucose-lowering drugs in routine care patients?
In routine clinical care, initiation of SGLT2 inhibitors may be associated with a lower risk of acute kidney injury compared to other novel glucose-lowering drugs.
This study of routine care patients initiating novel glucose-lowering drugs showed similar occurrence of AKI between therapies, and suggests lower risk for SGLT2i.
Alkas et al. (Fri,) studied this question.